Cargando…
Imatinib-induced irreversible interstitial lung disease: A case report
RATIONALE: Imatinib mesylate (imatinib) is a classic tyrosine kinase inhibitor used to treat chronic myeloid leukemia. Although it is well tolerated by most patients and helps in the achievement of complete remission, a few rare imatinib-associated adverse effects such as pulmonary interstitial fibr...
Autores principales: | Zhang, Ping, Huang, Jingfeng, Jin, Fangfang, Pan, Jiaohai, Ouyang, Guifang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407980/ https://www.ncbi.nlm.nih.gov/pubmed/30813141 http://dx.doi.org/10.1097/MD.0000000000014402 |
Ejemplares similares
-
A case report of nilotinib-induced irreversible interstitial lung disease
por: Cho, Jun Yeun, et al.
Publicado: (2022) -
Imatinib-Induced Interstitial Pneumonitis Successfully Switched to Nilotinib in a Patient with Prior History of Mycobacterium tuberculosis Infection
por: Luo, Zhuan-Bo, et al.
Publicado: (2017) -
Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection
por: Lee, Na-Ri, et al.
Publicado: (2015) -
Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report
por: Fenocchio, Elisabetta, et al.
Publicado: (2016) -
Clopidogrel-Induced Interstitial Lung Disease: A Case Report
por: An, Jin, et al.
Publicado: (2021)